Department of Medicine, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Tennessee Valley Healthcare System, Veterans' Affairs, Nashville, TN 37232, USA.
Int J Mol Sci. 2023 Nov 9;24(22):16109. doi: 10.3390/ijms242216109.
Penile squamous cell carcinoma is a rare disease with very limited data to guide treatment decisions. In particular, there is minimal evidence for effective therapies in the metastatic setting. Here, we present a case of metastatic penile squamous cell carcinoma with response to the Nectin-4 inhibitor enfortumab-vedotin-ejfv (EV). EV was selected due to the evidence of the high expression of Nectin-4 in squamous cell carcinomas, including penile carcinoma. The patient had both radiographic and symptomatic improvement after two cycles of treatment, despite having been treated with multiple prior lines of traditional chemotherapy. This case provides support for the use of antibody-drug conjugates (ADC), including EV, in this disease with few other options in the advanced setting. Further studies examining Nectin-4 and ADCs in penile squamous cell carcinoma should be completed, as high-quality evidence is needed to guide treatment after initial progression for these patients.
阴茎鳞状细胞癌是一种罕见疾病，可用于指导治疗决策的数据非常有限。特别是在转移性疾病中，有效的治疗方法的证据很少。在这里，我们报告了一例转移性阴茎鳞状细胞癌对 Nectin-4 抑制剂 enfortumab-vedotin-ejfv（EV）有反应的病例。选择 EV 是因为在包括阴茎癌在内的鳞状细胞癌中，Nectin-4 的高表达有证据支持。尽管患者已经接受了多种传统化疗，但在接受两个周期的治疗后，患者的影像学和症状均得到改善。该病例为在晚期疾病中使用抗体药物偶联物（ADC），包括 EV，提供了支持，因为在这种疾病中，在初始进展后，几乎没有其他选择。应进一步完成检查 Nectin-4 和 ADCs 在阴茎鳞状细胞癌中的研究，因为需要高质量的证据来指导这些患者的初始进展后的治疗。
